非酒精性脂肪性肝病新认识与再更名

杨蕊旭; 范建高

doi:10.3969/j.issn.1001-5256.2023.08.002

非酒精性脂肪性肝病新认识与再更名

DOI: 10.3969/j.issn.1001-5256.2023.08.002

杨蕊旭,
范建高^, ,

上海交通大学医学院附属新华医院消化内科, 上海 200092

基金项目:

国家自然科学基金 (81900507);

国家自然科学基金 (82170593);

国家科技部重点研发计划 (2021YFC2700802)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：杨蕊旭负责查找文献，撰写文稿；范建高负责审阅文稿及最后定稿。

详细信息

通信作者:
范建高，fanjiangao@xinhuamed.com.cn (ORCID: 0000-0002-8618-6402)

计量
- 文章访问数: 569
- HTML全文浏览量: 147
- PDF下载量: 244
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-29
- 录用日期: 2023-07-31
- 出版日期: 2023-08-20

A new understanding of nonalcoholic fatty liver disease and its rename

Ruixu YANG,
Jiangao FAN^{,
,}

Department of Gastroenterology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Research funding:

National Natural Science Foundation of China (81900507);

National Natural Science Foundation of China (82170593);

National Key Research and Development Program of China (2021YFC2700802)

More Information

Corresponding author: FAN Jiangao, fanjiangao@xinhuamed.com.cn (ORCID: 0000-0002-8618-6402)

摘要

摘要: 非酒精性脂肪性肝病是一种多系统受累的代谢性疾病，与胰岛素抵抗和遗传易感密切相关。目前非酒精性脂肪性肝病已成为我国乃至全球最常见的慢性肝病。本文就非酒精性脂肪性肝病的诊断和评估、非药物治疗、合并慢性乙型肝炎、靶向肠道菌群治疗策略以及更名争议等专家论坛的热点话题进行述评。
- 非酒精性脂肪性肝病 /
- 诊断 /
- 治疗学 /
- 命名
Abstract: Nonalcoholic fatty liver disease (NAFLD) is a metabolic disease with multisystem involvement and is closely associated with insulin resistance and genetic susceptibility. At present, NAFLD has become the most common chronic liver disease in China and worldwide. This article reviews the hot topics of various expert forums such as the diagnosis and evaluation of NAFLD, non-drug treatment, comorbidity with chronic hepatitis B, therapeutic strategies targeting intestinal flora and its rename of NAFLD.
- Non-alcoholic Fatty Liver Disease /
- Diagnosis /
- Therapeutics /
- Nomenclature

HTML全文

参考文献(24)

[1]	RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77(5): 1797-1835. DOI: 10.1097/HEP.0000000000000323.
[2]	FAN JG, YANG R. Global epidemic trend and Disease burden of nonalcoholic fatty liver disease[J]. Chin J Dig, 2023, 43(4): 248-252. DOI: 10.3760/cma.j.cn311367-20230202-00038. 范建高, 杨荣. 全球非酒精性脂肪性肝病的流行趋势与疾病负担[J]. 中华消化杂志, 2023, 43(4): 248-252. DOI: 10.3760/cma.j.cn311367-20230202-00038.
[3]	KWO PY, COHEN SM, LIM JK. ACG clinical guideline: evaluation of abnormal liver chemistries[J]. Am J Gastroenterol, 2017, 112(1): 18-35. DOI: 10.1038/ajg.2016.517.
[4]	WONG VW, CHAN RS, WONG GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial[J]. J Hepatol, 2013, 59(3): 536-542. DOI: 10.1016/j.jhep.2013.04.013.
[5]	WILLIAMS FR, BERZIGOTTI A, LORD JM, et al. Review article: impact of exercise on physical frailty in patients with chronic liver disease[J]. Aliment Pharmacol Ther, 2019, 50(9): 988-1000. DOI: 10.1111/apt.15491.
[6]	LAI JC, TANDON P, BERNAL W, et al. Malnutrition, frailty, and sarcopenia in patients with cirrhosis: 2021 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2021, 74(3): 1611-1644. DOI: 10.1002/hep.32049.
[7]	SUN C, FAN JG. Application of digital therapeutics in the treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2022, 38(4): 898-901. DOI: 10.3969/j.issn.1001-5256.2022.04.032. 孙超, 范建高. 数字疗法在非酒精性脂肪性肝病治疗中的应用[J]. 临床肝胆病杂志, 2022, 38(4): 898-901. DOI: 10.3969/j.issn.1001-5256.2022.04.032.
[8]	LI J, YANG HI, YEH ML, et al. Association between fatty liver and cirrhosis, hepatocellular carcinoma, and hepatitis B surface antigen seroclearance in chronic hepatitis B[J]. J Infect Dis, 2021, 224(2): 294-302. DOI: 10.1093/infdis/jiaa739.
[9]	MAO X, CHEUNG KS, PENG C, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: A systematic review and meta-analysis[J]. Hepatology, 2023, 77(5): 1735-1745. DOI: 10.1002/hep.32792.
[10]	SHAHEEN AA, ALMATTOOQ M, YAZDANFAR S, et al. Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers[J]. Aliment Pharmacol Ther, 2017, 46(6): 599-604. DOI: 10.1111/apt.14218.
[11]	SPRADLING PR, BULKOW L, TESHALE EH, et al. Prevalence and causes of elevated serum aminotransferase levels in a population-based cohort of persons with chronic hepatitis B virus infection[J]. J Hepatol, 2014, 61(4): 785-791. DOI: 10.1016/j.jhep.2014.05.045.
[12]	YANG RX, ZHOU D, FAN JG. Microbiome-based metabolite in the treatment of patients with non-alcoholic fatty liver diseases[J]. J Prac Hepatol, 2017, 20(6): 643-646. DOI: 10.3969/j.issn.1672-5069.2017.06.001. 杨蕊旭, 周达, 范建高. 靶向肠道菌群代谢产物防治非酒精性脂肪性肝病[J]. 实用肝脏病杂志, 2017, 20(6): 643-646. DOI: 10.3969/j.issn.1672-5069.2017.06.001.
[13]	SHEN F, CHEN JN, ZHENG RD, et al. Constitutional variation of gut microbiota detected by bar coded 454 pyrosequencing technology in patients with non-alcoholic fatty liver diseases[J]. J Prac Hepatol, 2015, 18(2): 145-149. DOI: 10.3969/j.issn.1672-5069.2015.02.010. 沈峰, 陈建能, 郑瑞丹, 等. 应用454测序技术评价非酒精性脂肪性肝病患者肠道菌群结构差异[J]. 实用肝脏病杂志, 2015, 18(2): 145-149. DOI: 10.3969/j.issn.1672-5069.2015.02.010.
[14]	GAO X, ZHU Y, WEN Y et al. Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials[J]. Hepatol Res, 2016, 46(12): 1226-1233 DOI: 10.1111/hepr.12671
[15]	ZHOU D, PAN Q, SHEN F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota[J]. Sci Rep, 2017, 7(1): 1529. DOI: 10.1038/s41598-017-01751-y.
[16]	ZHOU D, PAN Q, XIN FZ, et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier[J]. World J Gastroenterol, 2017, 23(1): 60-75. DOI: 10.3748/wjg.v23.i1.60
[17]	QIU LY, WANG YC. Nonalcoholic fatty liver diseases and the intestinal microecology: Current state of the art, controversies, and perspectives[J]. J Prac Hepatol, 2023, 26(3): 308-312. DOI: 10.3969/j.issn.1672-5069.2023.03.002. 邱丽瑛, 王迎春. 非酒精性脂肪性肝病与肠道微生态[J]. 实用肝脏病杂志, 2023, 26(3): 308-312. DOI: 10.3969/j.issn.1672-5069.2023.03.002.
[18]	LUDWIG J, VIGGIANO TR, McGILL DB et al. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease[J]. Mayo Clin Proc, 1980, 55: 434-438.
[19]	ESLAM M, SANYAL AJ, GEORGE J, et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. e1. DOI: 10.1053/j.gastro.2019.11.312.
[20]	ESLAM M, NEWSOME PN, SARIN SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[21]	RINELLA ME, LAZARUS JV, RATZIU V, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2023. DOI: 10.1097/HEP.0000000000000520. [Online ahead of print]
[22]	SARIN SK, ESLAM M, FAN JG, et al. MAFLD, patient-centred care, and APASL[J]. Hepatol Int, 2022, 16(5): 1032-1034. DOI: 10.1007/s12072-022-10408-6.
[23]	GEORGE J, LAU G, KAWAGUCHI T, et al. Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN)[J]. Hepatol Int, 2023, 17(3): 546-549. DOI: 10.1007/s12072-023-10530-z.
[24]	Expert Committee of the Fatty Liver Prevention and Treatment Special Fund of the China Health Promotion Foundation; Chronic Disease Management Branch of China Medical Biotechnology Association. Brief version of health management service package of metabolic dysfunction-associated fatty liver disease[J]. Chin J Health Manage, 2023, 17(3): 169-179. DOI: 10.3760/cma.j.cn115624-20230112-00026. 中国健康促进基金会脂肪肝防治专项基金专家委员会, 中国医药生物技术协会慢病管理分会. 代谢相关脂肪性肝病健康管理服务包(简版)[J]. 中华健康管理学杂志, 2023, 17(3): 169-179. DOI: 10.3760/cma.j.cn115624-20230112-00026.